Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models.
Engineered mutant α-ENaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models.
复制标题
DOI:
10.1126/sciadv.abc5911
复制
发表时间:
2020-11
期刊:
影响因子:
13.6
通讯作者:
Sahay G
中科院分区:
文献类型:
--
作者:
Mukherjee A;MacDonald KD;Kim J;Henderson MI;Eygeris Y;Sahay G
A nanoparticle delivered ENaC-inhibitory mRNA for the treatment of cystic fibrosis. Cystic fibrosis (CF) results from mutations in the chloride-conducting CF transmembrane conductance regulator (CFTR) gene. Airway dehydration and impaired mucociliary clearance in CF is proposed to result in tonic epithelial sodium channel (ENaC) activity, which drives amiloride-sensitive electrogenic sodium absorption. Decreasing sodium absorption by inhibiting ENaC can reverse airway surface liquid dehydration. Here, we inhibit endogenous heterotrimeric ENaC channels by introducing inactivating mutant ENaC α mRNA (αmutENaC). Lipid nanoparticles carrying αmutENaC were transfected in CF-based airway cells in vitro and in vivo. We observed a significant decrease in macroscopic as well as amiloride-sensitive ENaC currents and an increase in airway surface liquid height in CF airway cells. Similarly, intranasal transfection of αmutENaC mRNA decreased amiloride-sensitive nasal potential difference in CFTRKO mice. These data suggest that mRNA-based ENaC inhibition is a powerful strategy for reducing mucus dehydration and has therapeutic potential for treating CF in all patients, independent of genotype.
登录
查看更多内容
影响因子:
168.9
作者:
Heijerman, Harry G. M.;McKone, Edward F.;Mccoy, Karen S.
通讯作者:
Mccoy, Karen S.
影响因子:
24.3
作者:
Ho, LP;Samways, JM;Innes, JA
通讯作者:
Innes, JA
影响因子:
4.8
作者:
Kieber-Emmons, T;Lin, CM;Kleyman, TR
通讯作者:
Kleyman, TR
影响因子:
5.3
作者:
García-Añoveros, J;Samad, TA;Corey, DR
通讯作者:
Corey, DR
影响因子:
5.5
作者:
BOUCHER, RC;COTTON, CU;YANKASKAS, JR
通讯作者:
YANKASKAS, JR